| Human KRAS G12V (HLA-A*03:01) Tetramer Protein (LTP10258) |
| LTP10258 |
| 100ug |
|
$1350 In stock |
| Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
| Recombinant Human KRAS G12V (HLA-A*03:01) Tetramer Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide. |
| KRAS G12V (HLA-A*03:01) |
| Human |
| NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVGAVGVGK |
| Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide |
| The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on the Tris-Bis PAGE result. |
| Immobilized Human KRAS G12V (HLA-A*03:01) Tetramer, His Tag at 5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-KRAS G12V (HLA-A*03:01) Antibody, hFc Tag with the EC50 of 0.58ug/ml determined by ELISA (QC Test). The affinity constant of 42.3 nM as determined in SPR assay (Biacore T200). See testing image for detail. |
| C-His-Avi |
| Expi293 |
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Less than 1EU per ug by the LAL method. |
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipped at ambient temperature. |
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| |